<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106195</url>
  </required_header>
  <id_info>
    <org_study_id>KD025-205</org_study_id>
    <nct_id>NCT02106195</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris</brief_title>
  <official_title>A Phase 2a, Open-label Study to Evaluate the Safety and Tolerability of KD025 [Belumosudil] Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Who Have Failed First-line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kadmon Corporation, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kadmon Corporation, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the safety and tolerability of 200 mg of belumosudil&#xD;
      administered orally once daily for 28 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 2a, open-label, single-arm, safety and tolerability study of belumosudil&#xD;
      given daily for treatment of psoriasis.&#xD;
&#xD;
      Eight subjects with moderately severe psoriasis who have failed at least 1 line of systemic&#xD;
      therapy will be enrolled.&#xD;
&#xD;
      Treatment Period Eligible subjects who have failed at least 1 line of systemic therapy will&#xD;
      be entered and treated for 4 weeks with 200 mg of belumosudil given orally once daily (QD).&#xD;
&#xD;
      Subjects will undergo medical history evaluations, physical examinations, vital sign&#xD;
      measurements, weight, adverse event assessments, concomitant medication assessments, and&#xD;
      laboratory testing including but not limited to blood sample collection for hematology and&#xD;
      chemistry, urinalysis, coagulation, lipid panel, electrocardiogram, pregnancy test for&#xD;
      females of childbearing potential, testing with the Psoriasis Area and Severity Index (PASI)&#xD;
      scale and Physician Global Assessment (PGA) scale, and pharmacokinetic sampling.&#xD;
&#xD;
      Follow-up Period Follow-up visits will occur 30 days after the last dose of study drug in the&#xD;
      Treatment Period of the study. This visit must be done within ± 3 days of the scheduled&#xD;
      visit. The same assessments will be performed as in the Treatment Period.&#xD;
&#xD;
      The duration of the study is 12 weeks: up to 4 weeks for screening, 4 weeks of treatment, and&#xD;
      4 weeks of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 58 days (Treatment Period: 28 days; Post-treatment Period: 30 days)</time_frame>
    <description>To evaluate the safety and tolerability of 200 mg of belumosudil administered PO QD to subjects for treatment of psoriasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall PASI (Psoriasis Area and Severity Index) From Baseline to Day 28</measure>
    <time_frame>29 days (Day 1 to Day 29) and 59 days (30-day Follow-up)</time_frame>
    <description>Scale: 0 (no disease) to 72 (maximum disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Physician Global Assessment (PGA)</measure>
    <time_frame>29 days (Day 1 to Day 29)</time_frame>
    <description>PGA score after treatment with belumosudil 200 mg PO QD on Day 29. Categories: 100% = clear; 75% to 99% clearing (Excellent) = marked improvement, nearly normal skin texture, some erythema may be present; 50% to 74% clear (Good) = moderate improvement, plaque has cleared to point of small scattered papules with normal intervening epidermis; 25% to 49% clearing (Fair) = slight improvement, decrease in scaling and softening of plaque; 0% to 24% clearing (Poor) = little or no change in scaling, erythema, or plaque elevation; Worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax and Cmin</measure>
    <time_frame>28 days (Day 1 to Day 28)</time_frame>
    <description>Pharmacokinetic measures:&#xD;
Cmax = maximum observed plasma concentration; Cmin = minimum observed plasma concentration over 1 dosing period; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.&#xD;
Day 1 Cmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Cmax: 4 subjects each in KD025 and M2, and 1 subject in M1.&#xD;
Day 1 Cmin: 7 subjects each in KD025 and M2, and 3 subjects in M1. Day 28 Cmin: 4 subjects each in KD025 and M2, and 1 subject in M1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC(0-24) and AUC(Inf)</measure>
    <time_frame>28 days (Day 1 to Day 28)</time_frame>
    <description>Pharmacokinetic measures:&#xD;
AUC(0-24) = area under concentration time-curve from pre-dose (time 0) to 24 hours post-dose; AUC(inf) = area under concentration time-curve extrapolated from Day 1 to infinity; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Tmax</measure>
    <time_frame>28 days (Day 1 to Day 28)</time_frame>
    <description>Pharmacokinetic measure:&#xD;
Tmax = time of maximum observed plasma concentration. Day 1 Tmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Tmax: 4 subjects each in KD025 and M2, and 1 subject in M1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: t(1/2)</measure>
    <time_frame>28 days (Day 1 to Day 28)</time_frame>
    <description>KD025 = Parent Drug KD025; KD025 M2 = Metabolite M2; t(1/2) = apparent terminal elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Belumosudil 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belumosudil</intervention_name>
    <arm_group_label>Belumosudil 200 mg</arm_group_label>
    <other_name>Rezurock (brand name)</other_name>
    <other_name>KD025</other_name>
    <other_name>SLx-2119</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of moderately severe plaque psoriasis that has been stable for 6 months and&#xD;
             has failed at least one line of systemic therapy and is a candidate for additional&#xD;
             systemic therapy.&#xD;
&#xD;
          -  Had a PASI of ≥12&#xD;
&#xD;
          -  At least 10% of body surface area that is affected by plaque psoriasis.&#xD;
&#xD;
          -  Willing to avoid tanning devices or sun bathing.&#xD;
&#xD;
          -  Willing to forgo systemic and topical treatments for psoriasis during the course of&#xD;
             the study.&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Negative urine pregnancy test (for women of childbearing potential)&#xD;
&#xD;
          -  Agree to use a highly effective method of birth control (&lt; 1% per year failure rate)&#xD;
             during the study and for 1 month after the termination of the study.&#xD;
&#xD;
          -  Willing to complete all study measurements and assessments in compliance with the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-plaque or drug-induced psoriasis&#xD;
&#xD;
          -  Currently using corticosteroid or immunosuppressive therapy except for Class 5 or&#xD;
             weaker topical corticosteroids to the face, groin, or scalp&#xD;
&#xD;
          -  Using any topical therapy except for the following:&#xD;
&#xD;
               1. Class 5 or weaker steroids and phototherapy for 4 weeks prior to study entry&#xD;
&#xD;
               2. Immunosuppressive therapies for 4 weeks prior to study entry&#xD;
&#xD;
               3. Methotrexate, acitretin, or cyclosporine for 4 weeks prior to study entry&#xD;
&#xD;
               4. Biologic therapies for 3 months prior to study entry.&#xD;
&#xD;
          -  Concomitant condition requiring treatment with moderate to high dose steroids in the&#xD;
             12 weeks prior to screening.&#xD;
&#xD;
          -  Viral, fungal, or bacterial skin infection.&#xD;
&#xD;
          -  Pregnant or lactating woman.&#xD;
&#xD;
          -  Currently participating in another study with an investigational drug or within 28&#xD;
             days of study entry&#xD;
&#xD;
          -  History or other evidence of severe illness or any other conditions that would make&#xD;
             the subject, in the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  History or presence of any of the following:&#xD;
&#xD;
               1. Hepatic disease and or alanine aminotransferase (ALT) or aspartate&#xD;
                  aminotransferase (AST) &gt; 1.5 × the upper limit of normal (ULN) at screening&#xD;
&#xD;
               2. Renal disease and/or serum creatinine &gt; 1.5xULN at screening&#xD;
&#xD;
          -  Has QTc(f) intervals of &gt; 450 msec at the screening or pre-dose ECG&#xD;
&#xD;
          -  Subject is receiving any drugs known to prolong the QTc interval, including any&#xD;
             anti-arrhythmic medications within 2 weeks prior to screening&#xD;
&#xD;
          -  Subject is receiving any drug that is a strong CYP enzyme inhibitor&#xD;
&#xD;
          -  Subject is receiving any concomitant systemic drug that is metabolized by CYP enzyme&#xD;
&#xD;
          -  Previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2&#xD;
             inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UC Irvine Health, Dept of Dermatology</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <results_first_submitted>August 13, 2021</results_first_submitted>
  <results_first_submitted_qc>August 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2021</results_first_posted>
  <disposition_first_submitted>October 9, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>October 9, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 20, 2014</disposition_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Open-label, Phase 2a, single-arm study of subjects with moderately severe plaque psoriasis who had been stable for 6 months and had failed at least 1 line of systemic therapy. Subjects were recruited at 1 site in the U.S.</recruitment_details>
      <pre_assignment_details>Screening assessments occurred within 28 days prior to assignment and included informed consent, medical/demographic history, physical exam, vital signs, clinical laboratory tests, ECG, urine pregnancy, skin punch biopsy, PK, Psoriasis Area and Severity Index (PASI) scoring, Physician Global Assessment (PGA) scoring, and concomitant AE assessments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Belumosudil 200 mg PO QD</title>
          <description>The study consisted of 3 periods:&#xD;
Screening Period: screening within 28 days of first dose&#xD;
Treatment Period: 28 days of treatment with belumosudil 200 mg PO QD and an End of Treatment visit on Day 29 without dosing. Subjects had with safety (history, physical exams, blood samples for hematology, chemistry, and urinalysis), PK (Cmax, Tmax, AUC[0-24], AUC[0-inf]), efficacy (PASI and PGA); and PK sampling assessments.&#xD;
Post-treatment Period: follow-up safety visit 30 days after last dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5">Includes all 3 periods of study: Screening, Treatment, Post-treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Belumosudil 200 mg PO QD</title>
          <description>Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.6" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" lower_limit="31" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body mass index (kg/m^2)</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.42" spread="6.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body mass index (kg/m^2)</description>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.61" lower_limit="21.2" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability</title>
        <description>To evaluate the safety and tolerability of 200 mg of belumosudil administered PO QD to subjects for treatment of psoriasis</description>
        <time_frame>Up to 58 days (Treatment Period: 28 days; Post-treatment Period: 30 days)</time_frame>
        <population>Safety Population: All subjects who received at least 1 dose of belumosudil 200 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg PO QD</title>
            <description>Subjects who received at least 1 dose of belumosudil 200 mg orally daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability</title>
          <description>To evaluate the safety and tolerability of 200 mg of belumosudil administered PO QD to subjects for treatment of psoriasis</description>
          <population>Safety Population: All subjects who received at least 1 dose of belumosudil 200 mg</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥3 Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Overall PASI (Psoriasis Area and Severity Index) From Baseline to Day 28</title>
        <description>Scale: 0 (no disease) to 72 (maximum disease)</description>
        <time_frame>29 days (Day 1 to Day 29) and 59 days (30-day Follow-up)</time_frame>
        <population>All 8 subjects who received belumosudil 200 mg PO QD. 7 subjects available at follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg PO QD</title>
            <description>Subjects receiving 200 mg of belumosudil daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Overall PASI (Psoriasis Area and Severity Index) From Baseline to Day 28</title>
          <description>Scale: 0 (no disease) to 72 (maximum disease)</description>
          <population>All 8 subjects who received belumosudil 200 mg PO QD. 7 subjects available at follow-up visit.</population>
          <units>score on a scale from 0 to 72</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" spread="9.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Day 29 from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Follow-up from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Change from Baseline to Day 29</non_inferiority_desc>
            <p_value>0.324</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Physician Global Assessment (PGA)</title>
        <description>PGA score after treatment with belumosudil 200 mg PO QD on Day 29. Categories: 100% = clear; 75% to 99% clearing (Excellent) = marked improvement, nearly normal skin texture, some erythema may be present; 50% to 74% clear (Good) = moderate improvement, plaque has cleared to point of small scattered papules with normal intervening epidermis; 25% to 49% clearing (Fair) = slight improvement, decrease in scaling and softening of plaque; 0% to 24% clearing (Poor) = little or no change in scaling, erythema, or plaque elevation; Worse</description>
        <time_frame>29 days (Day 1 to Day 29)</time_frame>
        <population>All subjects who had PGA scoring at Day 29 and at 30-day Follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Belumosudil 200 mg PO QD</title>
            <description>Subjects receiving belumosudil 200 mg orally once daily for up to 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Physician Global Assessment (PGA)</title>
          <description>PGA score after treatment with belumosudil 200 mg PO QD on Day 29. Categories: 100% = clear; 75% to 99% clearing (Excellent) = marked improvement, nearly normal skin texture, some erythema may be present; 50% to 74% clear (Good) = moderate improvement, plaque has cleared to point of small scattered papules with normal intervening epidermis; 25% to 49% clearing (Fair) = slight improvement, decrease in scaling and softening of plaque; 0% to 24% clearing (Poor) = little or no change in scaling, erythema, or plaque elevation; Worse</description>
          <population>All subjects who had PGA scoring at Day 29 and at 30-day Follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29: 50% to 74% clearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: 25% to 49% clearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: 0 to 24% clearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up: 0 to 24% clearing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up: Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up: Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Cmax and Cmin</title>
        <description>Pharmacokinetic measures:&#xD;
Cmax = maximum observed plasma concentration; Cmin = minimum observed plasma concentration over 1 dosing period; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.&#xD;
Day 1 Cmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Cmax: 4 subjects each in KD025 and M2, and 1 subject in M1.&#xD;
Day 1 Cmin: 7 subjects each in KD025 and M2, and 3 subjects in M1. Day 28 Cmin: 4 subjects each in KD025 and M2, and 1 subject in M1.</description>
        <time_frame>28 days (Day 1 to Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Parent Drug KD025</title>
            <description>Study drug belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Metabolite M1</title>
            <description>Metabolite KD025 M1 of parent drug KD025.</description>
          </group>
          <group group_id="O3">
            <title>Metabolite M2</title>
            <description>Metabolite KD025 M2 of parent drug KD025.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Cmax and Cmin</title>
          <description>Pharmacokinetic measures:&#xD;
Cmax = maximum observed plasma concentration; Cmin = minimum observed plasma concentration over 1 dosing period; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.&#xD;
Day 1 Cmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Cmax: 4 subjects each in KD025 and M2, and 1 subject in M1.&#xD;
Day 1 Cmin: 7 subjects each in KD025 and M2, and 3 subjects in M1. Day 28 Cmin: 4 subjects each in KD025 and M2, and 1 subject in M1.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1240" spread="704"/>
                    <measurement group_id="O2" value="21.3" spread="10.9"/>
                    <measurement group_id="O3" value="221" spread="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="810" spread="475"/>
                    <measurement group_id="O2" value="15.0" spread="0"/>
                    <measurement group_id="O3" value="131" spread="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" spread="29.3"/>
                    <measurement group_id="O2" value="18.7" spread="9.16"/>
                    <measurement group_id="O3" value="21.1" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmin: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" spread="22.9"/>
                    <measurement group_id="O2" value="10.7" spread="0"/>
                    <measurement group_id="O3" value="17.6" spread="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: AUC(0-24) and AUC(Inf)</title>
        <description>Pharmacokinetic measures:&#xD;
AUC(0-24) = area under concentration time-curve from pre-dose (time 0) to 24 hours post-dose; AUC(inf) = area under concentration time-curve extrapolated from Day 1 to infinity; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.</description>
        <time_frame>28 days (Day 1 to Day 28)</time_frame>
        <population>AUC(0-24) Day 1: 7 subjects each in KD025 and M2. AUC(0-24) Day 28: 4 subjects in KD025 and 2 subjects in M2. AUC(inf): 4 subjects each in KD025 and M2. Neither AUC(0-24) nor AUC(inf) were calculated for M1.</population>
        <group_list>
          <group group_id="O1">
            <title>Parent Drug KD025</title>
            <description>Study drug belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Metabolite M2</title>
            <description>Metabolite KD025 M2 of parent drug KD025.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: AUC(0-24) and AUC(Inf)</title>
          <description>Pharmacokinetic measures:&#xD;
AUC(0-24) = area under concentration time-curve from pre-dose (time 0) to 24 hours post-dose; AUC(inf) = area under concentration time-curve extrapolated from Day 1 to infinity; KD025 = Parent Drug KD025; M1 = Metabolite KD025 M1; KD025 M2 = Metabolite M2.</description>
          <population>AUC(0-24) Day 1: 7 subjects each in KD025 and M2. AUC(0-24) Day 28: 4 subjects in KD025 and 2 subjects in M2. AUC(inf): 4 subjects each in KD025 and M2. Neither AUC(0-24) nor AUC(inf) were calculated for M1.</population>
          <units>ng x hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24): Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7360" spread="3180"/>
                    <measurement group_id="O2" value="1040" spread="545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-24): Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5500" spread="3790"/>
                    <measurement group_id="O2" value="162" spread="2320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(inf) from Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8230" spread="3600"/>
                    <measurement group_id="O2" value="1120" spread="680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: Tmax</title>
        <description>Pharmacokinetic measure:&#xD;
Tmax = time of maximum observed plasma concentration. Day 1 Tmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Tmax: 4 subjects each in KD025 and M2, and 1 subject in M1.</description>
        <time_frame>28 days (Day 1 to Day 28)</time_frame>
        <population>Day 1: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28: 4 subjects each in KD025 and M2, and 1 subject in M1.</population>
        <group_list>
          <group group_id="O1">
            <title>Parent Drug KD025</title>
            <description>Study drug belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Metabolite M1</title>
            <description>Metabolite KD025 M1 of parent drug KD025.</description>
          </group>
          <group group_id="O3">
            <title>Metabolite M2</title>
            <description>Metabolite KD025 M2 of parent drug KD025.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Tmax</title>
          <description>Pharmacokinetic measure:&#xD;
Tmax = time of maximum observed plasma concentration. Day 1 Tmax: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28 Tmax: 4 subjects each in KD025 and M2, and 1 subject in M1.</description>
          <population>Day 1: 7 subjects each in KD025 and M2, and 5 subjects in M1. Day 28: 4 subjects each in KD025 and M2, and 1 subject in M1.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="7.92"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.00" upper_limit="4.13"/>
                    <measurement group_id="O2" value="4.00" lower_limit="4.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="1.00" upper_limit="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK: t(1/2)</title>
        <description>KD025 = Parent Drug KD025; KD025 M2 = Metabolite M2; t(1/2) = apparent terminal elimination half-life</description>
        <time_frame>28 days (Day 1 to Day 28)</time_frame>
        <population>Pharmacokinetic measure:&#xD;
t(1/2) Day 1: 4 subjects for KD025 and 3 subjects for M2. t(1/2) Day 28: 3 subjects for KD025 and 1 subject for M2.&#xD;
t(1/2) was not calculated for M1.</population>
        <group_list>
          <group group_id="O1">
            <title>Parent Drug KD025</title>
            <description>Study drug belumosudil</description>
          </group>
          <group group_id="O2">
            <title>Metabolite M2</title>
            <description>Metabolite KD025 M2 of parent drug KD025.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: t(1/2)</title>
          <description>KD025 = Parent Drug KD025; KD025 M2 = Metabolite M2; t(1/2) = apparent terminal elimination half-life</description>
          <population>Pharmacokinetic measure:&#xD;
t(1/2) Day 1: 4 subjects for KD025 and 3 subjects for M2. t(1/2) Day 28: 3 subjects for KD025 and 1 subject for M2.&#xD;
t(1/2) was not calculated for M1.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>t-1/2: Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" spread="0.681"/>
                    <measurement group_id="O2" value="4.25" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t-1/2: Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.27" spread="0.692"/>
                    <measurement group_id="O2" value="2.26" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the signing of the informed consent form at Screening (up to 28 days before the first dose), through the Treatment Period (up to 28 days), and the Follow-up Period (30 days after the last dose of belumosudil). Maximum: 86 days</time_frame>
      <desc>The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 was used. The Clinical Symptom and Adverse Event Grading scale was used for grading toxicities.</desc>
      <group_list>
        <group group_id="E1">
          <title>Belumosudil 200 mg PO QD</title>
          <description>Subjects who received belumosudil 200 mg orally daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Same subject had SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Same subject had SAE</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <description>Same subject had SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <description>Same subject had SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Tooth ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding results. The sponsor cannot require changes to the study results in the communication except to remove sponsor's confidential information. Sponsor cannot unilaterally extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate VP, Clinical Operations</name_or_title>
      <organization>Kadmon Corporation, LLC</organization>
      <phone>833-900-5366</phone>
      <email>karin.herrera@kadmon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

